Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 22: 1575-1578, 1976;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by DeWolf, F.
Right arrow Articles by VanKempen, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by DeWolf, F.
Right arrow Articles by VanKempen, G.

Clinical Chemistry, Vol 22, 1575-1578, Copyright © 1976 by American Association for Clinical Chemistry

Determination of phenprocoumon, an anticoagulant, in human plasma

FA DeWolf and GMJ VanKempen

Phenprocoumon is extracted from acidified plasma, the organic phase evaporated, and part of the residue, in ethanol, is quantitatively applied to a thin-layer plate. After separation, the quantity of phenprocoumon is assayed by fluorescence densitometry in situ. Results are reproducible to about 2.5%. The lower limit of detection is 0.1 mg/liter, which makes the method fully applicable to human plasma, because therapeutic concentrations range from 1 to 3 mg/liter. Seven determinations can be made within 3 h. For toxicological purposes, a qualitative analysis can be done in a shorter time, because the phenprocoumon spots are visible under ultraviolet light at 254 nm.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1976 by the American Association for Clinical Chemistry.